
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Elocalcitol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Adge Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Adge has secured a global license to RO269228, a clinical stage oral small molecule originally developed by Roche for osteoporosis. RO269228, also known as elocalcitol, is a vitamin D analog which has demonstrated efficacy and safety in multiple Phase 2 ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 25, 2022
Lead Product(s) : Elocalcitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Adge Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
